cyrilzakka/clinical-trials huggingface dataset:
LumaENT and Patient Satisfaction

Patient satisfaction is an important metric currently used to rate quality of healthcare in hospitals. Maximizing patient satisfaction scores is therefore significantly beneficial to any hospital establishment. Recent studies have shown patient satisfaction depends on multiple factors, including patient involvement in treatment decision-making processes and patients' knowledge of treatment options. Internal review of departmental patient satisfaction survey scores revealed deficits in the aforementioned areas of patient satisfaction, with the domains of "how well concerns were addressed", "explanation of tests and procedures" and "effort to include patients in decisions" having the lowest scores on patient satisfaction surveys. This highlights the gap in patient satisfaction that the Otolaryngology department seeks to improve on, so as to maximize patient satisfaction, and in turn, the quality of healthcare provided.

The aim of this study is to assess the improvement in patient satisfaction scores that can be obtained by incorporating LUMA ENT™, a disease-specific multimedia patient education software, into the treatment decisions for thyroid disorders. LUMA ENT™ is a leading patient education software that provides visual anatomic animations of disease processes, disease progression and treatment options to improve patients' knowledge. Thyroid disorders have been chosen for study due to their high frequency of occurrence in the patient population and generalizability to a wide medical audience.

The investigators will perform a single-blinded randomized-controlled study of patients visiting the physician practices of the Department of Otolaryngology for management of thyroid disorders. Participants will be randomized into control and intervention groups. Upon completion of the routine physician-patient clinical encounter, the intervention group will view a 5- minute LUMA ENT™ video discussing their specific thyroid condition, its natural progression history, and treatment options. They will have an opportunity to ask the physician any further questions that arise from viewing the video. The control group will not view the LUMA ENT video. Patient satisfaction surveys will then be provided to both groups at the end of the visit as is routinely done and scores subsequently compared.


Eligibility Criteria:
Inclusion Criteria:

* Participants will be patients scheduled to visit the BJH/WU Department of Otolaryngology clinic for management of thyroid disorders (ranging from benign to cancerous nodules or masses) that will involve surgical interventions of complete or partial thyroidectomies.
* must be between the ages of 18 and 80
* may be male or female
* must understand spoken or written English language
* must be able to provide informed consent

Exclusion Criteria:

-Patients who have already undergone any thyroid surgery will be excluded
Effect of Electroacupuncture on Pain Threshold

This study is designed to evaluate whether or not electroacupuncture can have an effect on the pain threshold of the subject, as compared to sham treatment.

This study is utilized to evaluate the what effectiveness electroacupuncture has on pain threshold as compared to sham. The outcome measurement utilized will be a digital algometer. The electroacupuncture treatment will consist of a total of four electroacupuncture treatments stimulating acupuncture points LI4 and LI11, and will be given on the same upper extremity tested by the algometer. The algometer measurements will occur alone on the first week, prior to the treatments on the second and third week, and the final reading alone on the fourth week.

Eligibility Criteria:
Inclusion Criteria:

* Normal healthy subjects

Exclusion Criteria:

* Hypertension
* Heart Disease
* Pregnancy
* No spinal manipulation or other treatment or medication that could effect pain threshold
Does Extraction Difficulty of Mandibular Impacted Third Molars Mirror Post-op Outcomes?

The tooth of the patient who applies to the clinic for the impacted wisdom tooth will be classified according to Escoda's difficulty classification. Before the extraction, patients' interincisal, tragus-commissural, and lateral canthus-angulus distances, Oral Health Impact Profile -14 (OHIP-14) scores, and serum levels of CRP and D-Dimer will be measured.

Operation time will be recorded. After the operation, on 4th-day patients' patients' interincisal, tragus-commissural, and lateral canthus-angulus distances, Oral Health Impact Profile -14 (OHIP-14) scores, and serum levels of CRP and D-Dimer and Visual Analogue Scale (for pain) scores will be measured and recorded. On the 10th day, all these measurements will be repeated.

All recorded data will be evaluated for possible correlations based on extraction difficulties.


Eligibility Criteria:
Inclusion Criteria:

* Having extraction of only the mandibular third molar
* No systemic disease
* Signing an informed consent
* No dental phobia or anxiety
* No lesion around the impacted tooth
* Presence of adjacent second molar

Exclusion Criteria:

* Infection after surgery
* Alveolar osteitis
* Not to participate in any follow-up control appointments
Decision Making and Implementation of Aging-in-Place/Long Term Care Plans Among Older Adults

This study seeks to better understand how older adult aging-in-place/long term care decision making and implementation is impacted by age-related changes (e.g. cognition, health literacy, chronic conditions), social influences (e.g. caregivers/supporters), and environmental factors.

Subjects who are part of the National Institute on Aging (NIA)-funded LitCog study will be given access to PlanYourLifespan.org, a web-based decision-making and planning tool. Participants will be followed for up to 42 months to examine the mediating/moderating factors involved in decision-making, timing of decision implementation, and goal concordance. Findings have the potential to inform healthcare providers, caregivers, health/long term care insurers, area agencies on aging, and older adults nationally in supporting aging-in-place decisions and services use.

Eligibility Criteria:
Inclusion Criteria:

* Current participant in the LitCog Trial \[R01AG03611\]
* English-speaking
* Community-dwelling
* Currently use a computer or tablet with internet

Exclusion Criteria:

* Previous participation in the Advanced Planning for Home Services study \[IH-12-11-4259\]
Patient-Centered Chronic Pain Care

This study will adapt and scale existing AHRQ-supported interoperable CDS for patient-centered chronic pain care. The objective of this project is to study the adaptation and implementation of an existing interoperable CDS tool for pain treatment shared decision making, with tailored implementation support, in primary care clinical settings. The central hypothesis is that tailored implementation support will increase CDS adoption and shared decision making.

This study will adapt and scale the use of existing AHRQ-supported interoperable CDS that aids patient-centered chronic pain treatment decision making. The research will generate critical evidence on scalable strategies to implement and evaluate interoperable CDS in real-world settings across different types of EHRs. The pragmatic trial will enhance the reach of interoperable CDS to more diverse populations. Together, these efforts will lead to important new technology and evidence that patients, clinicians, and health systems can use to improve care for millions of Americans who suffer from pain and other chronic conditions.

Eligibility Criteria:
Inclusion Criteria:

* Primary care patients receiving care at a participating clinic
* Patients with chronic non-cancer musculoskeletal pain and with a recent history of opioid use

Exclusion Criteria:

* Due to the fact that the clinical decision support tool is currently available in English only, non-English speaking patients will not be eligible to participate
EpCAM and p53 Expressions in Infiltrating Duct Carcinoma of the Breast

Breast cancer represents the most frequently diagnosed cancer in women. It represents the 5th leading cause of cancer mortality all over the world.

In Egypt, breast cancer represents the 2nd most diagnosed cancer among all population. But among Egyptian females it represents the 1st diagnosed cancer representing 32.4%.

The main cause of death in breast cancer patients is tumor metastasis. Although only 5-10% of recently diagnosed breast cancer cases show metastasis to distant sites, but still there is a high risk for metastasis in patients with localized primary tumor following successful surgical management.

Epithelial cell adhesion molecule (EpCAM) is a cell adhesion molecule. It modifies cadherin mediated cell adhesion and it induces epithelial cell migration and proliferation. Some authors elucidate that EpCAM is involved in metastasis.

P53 is a known tumor suppressor gene involved in the control of cell cycle, DNA repair and apoptosis. It's one of the most mutated genes in cancer including breast cancer. Mutant p53 has a big role in tumor progression.


Eligibility Criteria:
Inclusion Criteria:

- Both incisional and excisional biopsy specimens. 2. All the studied cases include sufficient materials for the immunohistochemical study.

3. Complete clinical data.

Exclusion Criteria:

1. Patients with recurrence of the primary tumor.
2. Patients with a history of preoperative chemotherapy and/or radiotherapy.
3. Insufficient or tiny tissue biopsies
Dose-ranging Study to Evaluate the Effectiveness and Tolerability of MK0736 in Patients With Type 2 Diabetes Mellitus (T2DM) and Hypertension (0736-007)

The study will assess the efficacy and tolerability of MK0736 in patients with Type 2 Diabetes Mellitus and Hypertension who are on ongoing therapy with Angiotensin-Converting Enzyme or Angiotensin Receptor Blocker. After a 3 to 5 week pre-randomization phase, patients will be randomized to either MK0736 (3 doses), placebo, or hydrochlorothiazide (HCTZ). The study will also include a 3 week, posttreatment follow-up period.


Eligibility Criteria:
Inclusion Criteria:

* Must be 18 to 75 years of age
* Type 2 Diabetes Mellitus (Glycohemoglobin \[A1CHbA1c\]: 7 to 10%)
* Hypertension: Diastolic blood pressure (DBP; 85 to 99 mm Hg) and systolic blood pressure (SBP; 120 to 159 mm Hg)
* LDL-C \< 140 mg/dL
* On stable treatment with an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Exclusion Criteria:

* History of Type I Diabetes mellitus or ketoacidosis
* Patients taking 3 or more blood pressure lowering medications
* Have severe chronic heart failure
* History of certain diseases or conditions such as cardiac arrhythmias, heart attack, stroke, unstable angina, or decompensated vascular disease
* History of cancer within the last 5 years
* Human immunodeficiency virus (HIV) Positive
* Have received treatment with any investigational drugs within the past 30 days
* History of alcohol or drug abuse within the past 3 years
* Body Mass Index ( BMI) \>= 41 kg/m2
Brighter Bites - Access, Continuity and Education With Fruits and Vegetables

The purpose of the research is to find out how well a new nutrition program works for elementary school students and their families. This program is called Brighter Bites. Brighter Bites is a school-based program that teaches students and their parents about the importance of eating fresh fruits and vegetables and how to prepare them in tasty, healthy ways. This project is being carried out at six elementary schools in Houston, Texas. Up to 600 first grade students and their parents/guardians are expected to join this project.


Eligibility Criteria:
Inclusion Criteria:

* Child is in enrolled in the 1st grade in the participating school

Exclusion Criteria:

* None
A Study to Investigate the Interaction Between JNJ-64155806 and Ethinylestradiol/Drospirenone in Healthy Females

The primary purpose of this study is to evaluate the effect of single and multiple doses of JNJ-64155806 on the steady-state pharmacokinetics (PK) of ethinylestradiol and drospirenone and vice versa in healthy female participants.


Eligibility Criteria:
Inclusion Criteria:

* Participant must be female of childbearing potential with a normal menstrual cycle, not using oral contraceptives in the 30 days prior to screening
* Participant must have a body mass index (BMI; weight in kilogram (kg) divided by the square of height in meters \[m\]) of 18.0 to 30.0 kg/m\^2, extremes included, and a body weight not less than (\<) 50.0 kg
* Participant must be willing and able to adhere to the requirements, instructions, and prohibitions and restrictions specified in this protocol, and is likely to complete the study as planned
* Participant must be healthy on the basis of physical examination, medical history, vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory tests performed at screening. If the results of the biochemistry panel, hematology, or urinalysis are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant. This determination must be recorded in the participant's source documents and initialed by the investigator
* Participants must be willing to start ethinylestradiol/drospirenone contraception during the COCP lead-in and JNJ-64155806 + COCP coadministration phases

Exclusion Criteria:

* Participant is a woman who is pregnant as confirmed by a positive beta human chorionic gonadotropin (beta-hCG) laboratory test, or who was pregnant within 6 months prior to study start, or who is breast-feeding, or who is planning to become pregnant from signing of the informed consent form (ICF) until 90 days after the last dose of study drug
* Participant with creatinine clearance of less than (\<) 90 milliliter per minute (mL/min) (Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] equation)
* Participant with a clinically significant cardiovascular, respiratory, renal, gastrointestinal, hematologic, neurologic (syncope or seizures), thyroid, or any other medical illness or psychiatric disorder, as determined by the investigator and/or sponsor's medical monitor
* Participant has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (example, compromise the well-being), or that could prevent, limit, or confound the protocol-specified assessments
* Participant with currently active gynecological disorders including, but not limited to, vaginal bleeding without an obvious reason and hyperprolactinemia with or without galactorrhea
Risk Stratification of Patients With Suspected COVID-19 Presenting to the ED

This project is an unfunded collaboration of approximately 30 emergency departments across Europe led by the EUSEM research network. It involves collection of data in relation to determining the epidemiology and outcome of adult patients who present to emergency departments with a suspected Covid infection.

Over the past 6 months, the world has faced a novel infection disease outbreak, due to a novel coronavirus, the severe acute respiratory syndrome coronavirus (SARS-CoV2), with a massive impact on healthcare resource.

In Europe, numbers of confirmed cases continue to rise. Europe is currently one of the regions with the highest number of Covid-19 cases and deaths due to this emergent diseases.

Most COVID-19 infected patients present with mild to moderate acute respiratory symptoms, including cough, fever, dyspnea and pneumonia. About 20% will present with severe or critical manifestations of the disease, including pneumonia, respiratory failure and acute respiratory distress syndrome (ARDS).

Anticipating the needs for hospitalization in ward and/or intensive care is crucial.

Emergency departments are at the front line for triaging patients with suspected Covid-19 and referring them to the appropriate level of care.

In Europe, the number of ED patients with suspected Covid-19 is variable; rate of hospitalization from ED reaches 40% for this population.

Risk stratification and management decisions of patients presenting to the ED with suspected COVID-19 is a challenge for emergency physicians.

Eligibility Criteria:
Inclusion Criteria:

* Adult patients (\>= 18 years old) attending the ED with a clinical suspicion of COVID-19 based on the presence of the following criteria
* Fever \>= 38 °C
* respiratory symptoms (dyspnea, cough, expectorations)
* any other symptoms suggestive of COVID-19 including digestive signs (diarrhea, anosmia...)

Exclusion Criteria:

* None
Plasma Biomarkers C-RAC, ICORG 12-27, V1

This is an exploratory, translational, non-interventional and multi-centre clinical study.

Cohort A will consist of 100 CRAC patients with stage II/III resectable disease due for adjuvant chemotherapy.

Cohort B will consist of 30 patients with stage II resectable disease for observation only.

Both cohorts will have a follow up period of up to 2 years, post chemotherapy for cohort A and post resection for cohort B.

Eligibility Criteria:
Inclusion Criteria:

* Patient must be able to give written informed consent
* Histologically or cytologically confirmed CRAC
* Cohort A: colorectal cancer patients with stage II/III resectable disease due for adjuvant chemotherapy OR Cohort B: colorectal cancer patients with stage II resectable disease for observation only
* Age ≥ 18 years
* Treatment with curative intent
* Eastern Cooperative Oncology Group (ECOG) Performance status 0 - 2

Exclusion Criteria:

* Presence of a medical or psychiatric condition, which, in the opinion of the investigator, would potentially pose a risk to the patient when participating in this trial
* Evidence of a metastatic disease
Effects Neuromuscular Taping Technique on Upper Limbs Edema in Cardiac Surgery Patients

This study aims to verify the efficacy of the decompression technique of neuromuscular taping on cardiac surgery patients in whom edema of the upper limbs occurs due to post-operative water overload.


Eligibility Criteria:
Inclusion Criteria:

* Cardiac surgery patients with postoperative edema of the upper limbs due to water overload

Exclusion Criteria:

* absence of edema,
* previous mastectomy and lymphadenectomy,
* surgery or fractures or infection of the upper limb,
* previous or current deep vein thrombosis.
Post-extubation Boussignac CPAP System in Adults With Moderate to Severe Obstructive Sleep Apnea

The purpose of this study is to assess the efficacy of the Boussignac positive airway pressure system (a mask) applied immediately following post-operative extubation in improving lung function in patients with obstructive sleep apnea (OSA). Assessments will be done before surgery and then at 1, 2 and 24 hours following extubation and will be compared to standard care for perioperative airway support. The study aims to give a broader and more inclusive picture (than the current literature) in terms of whether the Boussignac CPAP system should be considered for utilization by anesthesiologists caring for surgical patients with OSA.


Eligibility Criteria:
Inclusion Criteria:

-\> 18 years of age

* ASA II-IV
* Previous diagnosis of moderate to severe obstructive sleep apnea
* diagnosed via polysomnography
* BMI \< 40
* scheduled for an abdominal or peripheral surgical procedure requiring endotracheal intubation and admission to hospital

Exclusion Criteria:

* BMI \> 40
* Age \<18 years
* inability to provide signed informed consent
* intra-thoracic
* head or neck surgery
* contraindication for immediate post-extubation application of CPAP
* not expected to be eligible for timely extubation following the surgical procedure
Fetal Cardiovascular Response to Maternal Exercise During Third Trimester

The purpose of this study was to examine the behavior of the fetal heart rate in response to different intensities of acute maternal exercise in training and non-training pregnant women

Fetal heart rate is considered an important index of fetal well-being, especially during the third trimester of pregnancy (Rodney JR, Huntley BJ, Rodney WM, 2012). An increase in the FHR of 5-25 beats per min (bpm) in response to maternal exercise has been established as a normal reaction(Riemann,Kanstrup Hansen, 2000)however the normal FHR response to maternal exercise has remained unclear for several reasons

Most of the studies are focused on obtain data in order to examine the fetal heart rate response to maternal exercise using cardiotocography measurements prior to and following maternal exercise

Eligibility Criteria:
Inclusion Criteria:

* Being healthy and able to exercise following American College of Obstetricians and Gynecologists (ACOG) guidelines
* Being able to communicate in spanish
* Giving birth at Hospital Universitario de Fuenlabrada

Exclusion Criteria:

* Multiparity
* Obstetrician complications
* Being interested in the study after 18 weeks
* Not being regular in physical exercise program
* Younger than 18 years old
Use of Minocycline in Intracerebral Hemorrhage

To date, no neuroprotective drugs have demonstrated clinical efficacy in intracerebral hemorrhage (ICH). This study will use intravenous (IV) minocycline in ICH to evaluate for (1) safety/ tolerability and (2) evaluate for clinical efficacy

Intracerebral hemorrhage (ICH) remains a devastating neurological disorder with high mortality and poor prognosis with unchanged mortality rates (53-59%). Acute treatment options for ICH remain supportive with no available effective drug or surgical therapy. All trials so far have failed to improve clinical outcome in randomized, double-blinded trials. However, one area of interest has been maintaining the integrity of the blood-brain-barrier (BBB) and preventing the growth of vasogenic edema. Matrix metalloproteinases (MMP) are a family of ubiquitous zinc-dependent endopeptidase enzymes whose primary function is the digestion of collagen type IV, laminin, and fibronectin for the purpose of remodeling extracellular basal lamina. Elevated MMP-9 as a pathological process associated with larger hematoma volume, larger perihematomal edema, and poorer clinical outcome in intracerebral hemorrhage is well documented in animal models and patients. One particular MMP-9 inhibitor gaining usage in cerebrovascular disease is minocycline. Normally FDA-approved for bacterial infection and acne vulgaris, minocycline has also been found to be both a safe and effective treatment in ischemic stroke; its potential role as a neuroprotectant in ischemic stroke is currently being tested in a large, randomized, double-blinded trial. Minocycline's beneficial role as a neuroprotectant may also extend to ICH. By inhibiting MMP-9, minocycline may decrease BBB permeability, resulting in less perihematomal edema and decreased mass effect. Although numerous animal ICH models support minocycline's role as an inhibitor of MMP-9 and neuroprotectant, its use has never been studied in humans with ICH.

Eligibility Criteria:
Inclusion criteria:

1. Age 18-80 yo
2. Acute neurological deficit with corresponding ICH noted on head CT
3. Glasgow Coma Scale (GCS) \> 8
4. Onset of symptoms within 12 hrs
5. \< 30 ml of blood noted on initial CTH (30 ml hematoma volume is a noted independent marker between good and poor clinical outcome)
6. ICH score \< 3
7. English/ Spanish speaking

Exclusion Criteria:

1. Allergy to tetracycline and tetracycline analogues
2. Pregnancy or suspected pregnancy
3. Hepatic and/or renal insufficiency (LFTs 3x greater than upper limit of normal; creatinine \> 2 mg/dL)
4. Thrombocytopenia (plt count \< 75,000)
5. History of intolerance to minocycline
6. Baseline modified Rankin score \> 1
7. Stuporous or comatose (GCS \< 8)
8. Presence of concomitant serious illness that would confound study, including serious psychiatric disease or prior suicide attempts.